Project description:Hematopoietic stem cells (HSCs) are characterized by their ability to generate all blood cells while retaining their self-renewal capacity. While it is convenient to believe that HSCs represent a homogenous population, several evidences do not support this notion. Here we identified and characterized a HSC population that expressed CD93 on their membrane. This population showed strong molecular dHSC signature, combined with activation features. Thereby, suggesting that they represent an intermediate state between quiescent and active HSCs being more prone to respond upon alterations in the hematopoietic lineage
Project description:Hematopoietic stem cells (HSCs) are characterized by their ability to generate all blood cells while retaining their self-renewal capacity. While it is convenient to believe that HSCs represent a homogenous population, several evidences do not support this notion. Here we identified and characterized a HSC population that expressed CD93 on their membrane. This population showed strong molecular dHSC signature, combined with activation features. Thereby, suggesting that they represent an intermediate state between quiescent and active HSCs being more prone to respond upon alterations in the hematopoietic lineage
Project description:Leukemia stem cells (LSCs) share several crucial properties with hematopoietic stem cells (HSCs) including self-renewal, cell cycle quiescence, and expression of a CD34+CD38- immunophenotype, which complicates efforts to eradicate AML by therapeutically targeting LSCs without adversely affecting HSCs. Here we report that CD93, a C-type lectin transmembrane receptor, is preferentially expressed on the cell surface of LSCs compared with HSCs in the genetic subtype of AML with genomic rearrangements of the MLL gene. LSCs that selectively express CD93 are actively cycling, and highly enriched for xeno-engraftment potential, yet comprise a minor component of an otherwise quiescent CD34+CD38- compartment of human AML. Notably, CD93 is required for LSC function in MLL leukemogenesis, and is not simply a passive surface marker co-expressed on LSCs. Thus, CD93 selectively marks and essentially maintains LSCs, and identifies them as predominantly cycling, non-quiescent leukemia-initiating cells in MLL-rearranged AML.
Project description:IL-17D/CD93 axis was essential for ILC3s hemostasis. In order to further understand how IL-17D-CD93 axis regulate ILC3s function, we conducted RNA-seq analysis of ILC3s.